Pro Share Advisors LLC Morphic Holding, Inc. Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$26.12 - $34.07 $47,747 - $62,279	-1,828 Reduced 17.65%	8,531 $290,000
Q1 2024 May 08, 2024	BUY	$26.64 - $40.31 $29,277 - $44,300	1,099 Added 11.87%	10,359 $364,000
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $184,737 - $287,060	9,260 New	9,260 $267,000
Q2 2023 Aug 10, 2023	BUY	$34.33 - $62.11 $39,513 - $71,488	1,151 Added 19.95%	6,921 $396,000
Q1 2023 May 11, 2023	BUY	$26.01 - $48.69 $150,077 - $280,941	5,770 New	5,770 $217,000
Q2 2022 Aug 01, 2022	SELL	$19.74 - $43.01 $153,991 - $335,521	-7,801 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$36.25 - $52.02 $73,587 - $105,600	-2,030 Reduced 20.65%	7,801 $313,000
Q4 2021 Feb 08, 2022	BUY	$43.27 - $65.72 $425,387 - $646,093	9,831 New	9,831 $466,000
Q3 2021 Nov 12, 2021	SELL	$53.61 - $67.5 $288,368 - $363,082	-5,379 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$45.13 - $64.99 $74,825 - $107,753	1,658 Added 44.56%	5,379 $309,000
Q1 2021 May 14, 2021	BUY	$29.77 - $84.85 $110,774 - $315,726	3,721 New	3,721 $235,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.